Destiny Pharma plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DEST.L research report →
Companywww.destinypharma.com
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.
- CEO
- Christopher John Tovey BSc
- IPO
- 2017
- Employees
- 15
- HQ
- Brighton, GB
Price Chart
Valuation
- Market Cap
- $2.87M
- P/E
- -0.48
- P/S
- 3.46
- P/B
- 0.30
- EV/EBITDA
- 0.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.25%
- Op Margin
- -790.08%
- Net Margin
- -680.30%
- ROE
- -67.28%
- ROIC
- -62.74%
Growth & Income
- Revenue
- $831.55K · 438.22%
- Net Income
- $-5,657,036 · 13.02%
- EPS
- $-0.06 · 32.61%
- Op Income
- $-6,569,960
- FCF YoY
- 9.66%
Performance & Tape
- 52W High
- $84.00
- 52W Low
- $3.00
- 50D MA
- $7.96
- 200D MA
- $36.77
- Beta
- 0.22
- Avg Volume
- 1.08M
Get TickerSpark's AI analysis on DEST.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DEST.L Coverage
We haven't published any research on DEST.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DEST.L Report →